Are Peptides FDA-Approved? Some Are. Most of What Is Sold Online Is Not.

Some peptides are FDA-approved drugs: insulin, semaglutide, tesamorelin and bremelanotide are all peptide-based medicines sold under labels the agency reviewed. Most of the "research peptides" sold online, including BPC-157 and TB-500, are not approved for any human use, and the advisory committee vote of July 2026 did not change that.

The rest of this page explains why both statements are true at once, and why the word "peptide" on its own tells you almost nothing about legal status.

"Peptide" is a chemistry word, not a legal status

A peptide is a short chain of amino acids. The FDA draws its own line at 40: under a rule that took effect on March 23, 2020, an amino acid chain longer than 40 residues is a protein and is regulated as a biological product, while a shorter chain is a peptide. Insulin, whose two chains of 21 and 30 residues the agency counts together as 51, crossed that line, and insulin products have been regulated as biologics since that date.

That detail matters for one reason. Whether a molecule is a peptide is a question about its structure. Whether it is approved is a question about a specific product: a named manufacturer, a defined formulation, a reviewed label and a stated indication. The FDA approves products, not molecule names, and a vial carrying the same name as an approved drug does not inherit the approval.

Peptides that are FDA-approved

Peptide drugs are an established part of medicine. A 2021 review in Nature Reviews Drug Discovery (Muttenthaler et al.) counted more than 80 peptide drugs that have reached the market since insulin was introduced. Four examples show the range:

Insulin. The original peptide medicine, in use for a century and now regulated as a biologic under the 40-amino-acid rule above.

Semaglutide. Approved for type 2 diabetes and, as Wegovy on June 4, 2021, for chronic weight management in adults meeting the label's criteria.

Tesamorelin. Approved in November 2010 as Egrifta, for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is a growth-hormone-releasing factor analog, and the label is that narrow.

Bremelanotide. Approved on June 21, 2019 as Vyleesi, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The same molecule circulates in the research market as PT-141. Material sold under that name is not Vyleesi and carries none of its approval.

Others in common use include leuprolide, octreotide and teriparatide. In every case the approval covers one manufactured product with a reviewed label, studied in named trials, for a defined use.

What most research peptides are

Unapproved, in the plain sense: no application has been filed and reviewed for any human use. The FDA's own briefing documents for its July 2026 advisory meeting show how thin the record can be. For BPC-157, the agency found five small published human reports, most of them meeting abstracts or single-clinic case series, and concluded there was insufficient clinical safety information to characterize the compound. For TB-500, it identified no human exposure data at all.

"Research use only" is a real category, defined by what material is marketed and used for. It is not an approval and not a workaround for one. When the FDA wrote to five online peptide sellers in August 2026, it said their research-use disclaimers did not change its finding that the products were intended for people, based on what the websites said around the label. Our field guide on what research use only means and our coverage of those warning letters go further.

What 2026 changed

Most of this year's headlines concern compounding, which is a separate lane from approval. A state-licensed compounding pharmacy can prepare a medication for an individual patient with a prescription, using bulk ingredients the FDA allows. The relevant list is the 503A bulks list, and the sequence this year ran as follows:

2023. The FDA placed BPC-157 and a group of other peptides in Category 2 of its interim compounding policy, the category for substances that may present significant safety risks.
February 27, 2026. Health Secretary Robert F. Kennedy Jr. said about 14 of the 19 restricted peptides would be made more accessible through compounding.
April 15, 2026. The FDA gave notice that it would remove 12 peptides from Category 2 because their nominators had withdrawn the nominations. They were not moved to Category 1, the category where the agency exercises enforcement discretion, with one exception: the FDA's list as updated on May 14 shows GHK-Cu back in Category 1 for non-injectable routes only.
July 23 and 24, 2026. The Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. It voted against emideltide. FDA staff had proposed against including them.
October 7, 2026. The Washington Post reported that the administration is drafting a temporary path for some restricted peptides while rules are written. We cover that report separately.

What it did not change

The advisory vote was a recommendation. It did not add anything to the 503A bulks list, which requires FDA rulemaking, and we could find no proposed or final rule as of this writing. Our coverage of the meeting walks through the process.

More importantly for this question, nothing in that sequence is an approval. Even a final listing would only allow compounding pharmacies to prepare a substance for individual prescribed patients. It would not create an FDA-approved drug, would not establish that any compound works, and would not change the status of material sold as research chemicals outside pharmacy channels. Approval comes from a reviewed application backed by clinical trials, and none of the six recommended peptides has one.

Frequently asked questions

Is BPC-157 FDA-approved?

No. BPC-157 is not approved for any human use in the United States. It was recommended for the 503A compounding list by an advisory committee in July 2026, against FDA staff advice, and that recommendation is not an approval.

Is semaglutide a peptide?

Yes. Semaglutide is a modified peptide and the active ingredient in FDA-approved products, including Wegovy. The approval belongs to those products, not to material sold under the molecule's name.

Is PT-141 the same as Vyleesi?

They share a molecule, bremelanotide. Vyleesi is the FDA-approved product. A vial labeled PT-141 from a research supplier is a different product and is not approved.

Did the FDA approve peptides in 2026?

No new approvals came out of the 2026 compounding process. The agency removed some peptides from a restricted compounding category and an advisory committee recommended six for the bulks list. Neither step is a drug approval.

Sources:

Nothing here is legal or medical advice. Research use only.

For research use only · Not for human or veterinary use · No research compound discussed here is FDA-approved for any indication